SMISEK JEFFERY A 4
4 · Finch Therapeutics Group, Inc. · Filed Mar 25, 2021
Insider Transaction Report
Form 4
SMISEK JEFFERY A
Director
Transactions
- Conversion
Common Stock
2021-03-23+272,245→ 1,606,306 total(indirect: See footnote) - Conversion
Series B Preferred Stock
2021-03-23−141,928→ 0 total(indirect: See footnote)→ Common Stock (141,928 underlying) - Conversion
Series D Preferred Stock
2021-03-23−272,245→ 0 total(indirect: See footnote)→ Common Stock (272,245 underlying) - Conversion
Common Stock
2021-03-23+894,955→ 894,955 total(indirect: See footnote) - Conversion
Common Stock
2021-03-23+297,178→ 1,334,061 total(indirect: See footnote) - Conversion
Common Stock
2021-03-23+141,928→ 1,036,883 total(indirect: See footnote) - Purchase
Common Stock
2021-03-23$17.00/sh+88,235$1,499,995→ 1,694,541 total(indirect: See footnote) - Conversion
Series A Preferred Stock
2021-03-23−894,955→ 0 total(indirect: See footnote)→ Common Stock (894,955 underlying) - Conversion
Series C Preferred Stock
2021-03-23−297,178→ 0 total(indirect: See footnote)→ Common Stock (297,178 underlying)
Footnotes (2)
- [F1]Each share of Series A Preferred Stock, Series B Preferred Stock, Series C Preferred Stock and Series D Preferred Stock automatically converted into shares of Common Stock upon the closing of the Issuer's initial public offering for no additional consideration, on a one-for-one basis, and had no expiration date.
- [F2]The securities are held by Flight Partners Management LLC ("Flight Partners Capital"). The Reporting Person is the president of Flight Partners Capital.